Flonoltinib Maleate Oral Regimens in Patients With Myelofibrosis
Key claim: A dose-finding clinical trial is comparing three daily oral doses of flonoltinib maleate for control of myelofibrosis symptoms and organ-damage signs, and for safety, in adults whose disease was not adequately controlled by the most common approved therapy.
Abstract
The goal of this clinical trial is to learn which of three different doses of Flonoltinib Maleate taken by mouth daily works best to treat adult patients with myelofibrosis in whom the most common approved therapy has failed to adequately control the disease. It will also learn about the safety of the three different daily doses of Flonoltinib Maleate. The main questions it aims to answer are:
Which dose is the best at controlling the symptoms and signs of organ damage caused by myelofibrosis? What medical problems do participants have when taking the three different doses of Flonoltinib Maleate? Researchers will compare the three different doses of Flonoltinib Maleate to see which dose is best to treat patients with myelofibrosis.
Participants will:
Take Flonoltinib Maleate every day for as long as it seems to be of benefit to them in terms of controlling myelofibrosis.
Visit the clinic for checkups and tests after giving fully informed written consent confirming that they would like to consider entering the study.
Visit the clinic for checkups and tests when on the study once every 2 weeks for the first 2 months, every 4 weeks after that, and when coming off study therapy.
Keep a diary of their symptoms.
Why this matters
Patients with myelofibrosis who lose response to or cannot tolerate the standard JAK1/2 inhibitor have few well-validated next-line oral options, so any new agent entering dose-finding in that exact setting expands the pipeline of potential salvage therapies. Because this study is still at the dose-selection stage without efficacy or safety readouts, it belongs on the wiki as a placeholder to be populated once outcomes are reported.